Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
Society of Gynecologic Oncology (SGO)
SGO 2020
SGO 2020
Promising Results Seen with Maintenance Rucaparib in Patients with Ovarian Cancer and Non-BRCA HRR Gene Mutations
SGO 2020
In a small subgroup of patients from the phase 3 ARIEL3 trial, rucaparib improved a number of clinically meaningful end points in addition to progression-free survival.
Read More ›
Pooled Analysis Supports Suggested Rucaparib Starting Dose in Recurrent Ovarian Cancer
SGO 2020
An analysis of patients with recurrent ovarian carcinoma supports the approved starting dose of rucaparib at 600 mg twice daily.
Read More ›
Can PARP Inhibitor Eligibility Be Expanded in Ovarian Cancer?
SGO 2020
Analysis of mutations in homologous recombination deficiency–associated genes in ovarian cancer suggest PARP inhibitors may only benefit a small subset of patients.
Read More ›
Measuring Utilization of Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer
SGO 2020
Although many patients eligible for maintenance therapy do not receive it, research shows that when utilized, maintenance with PARP inhibitors or bevacizumab extends survival.
Read More ›
Study Shows High Clinical and Financial Burden of PARP Inhibitors
SGO 2020
A real-world, retrospective analysis from community oncology practices reveals a higher clinical and financial burden with PARP inhibitors than reported in clinical trials.
Read More ›
Extrapolation Methods Could Help Inform Ovarian Cancer Treatment, Management
SGO 2020
One method used to extrapolate long-term survival data from a phase 3 clinical trial aligned closely with overall survival data from the SEER database, suggesting its utility in informing future treatment and management models when trial data are not yet mature.
Read More ›
Niraparib/Bevacizumab Combination Appears Safe and Effective in Advanced Ovarian Cancer
SGO 2020
Phase II OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab.
Read More ›
Study Finds Genomic Instability Scores Used in Clinical Trials Are Not Equivalent
SGO 2020
Compared with myChoice HRD, percentage of loss of heterozygosity score identifies a significantly smaller proportion of
BRCA
-mutated tumors.
Read More ›
No Difference in Survival Between Olaparib Monotherapy and Standard of Care
SGO 2020
In patients with platinum-sensitive recurrent epithelial ovarian cancer, olaparib monotherapy did not improve survival over standard-of-care chemotherapy.
Read More ›
Longer Time to Post–PARP Inhibitor Therapy Associated with Better Tolerance to Subsequent Therapy
SGO 2020
After discontinuing treatment with a PARP inhibitor, waiting longer to initiate subsequent therapy was associated with better tolerance to post–PARP inhibitor therapy, with no negative impact on progression-free survival.
Read More ›
Page 1 of 2
1
2
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us